Betaine Anhydrous

What other names is Betaine Anhydrous known by?

2(N,N,N-trimethyl)ammonium-acetate, Betaína Anhidra, Bétaïne Anhydre, Betaine Anhydrous, Bétaïne de Glycine, Bétaïne de Glycocoll, Cystadane, Glycine Betaine, Glycocoll Betaine, Glycylbetaine, Lycine, Oxyneurine, TMG, Trimethyl Glycine, Trimethylbetaine, Trimethylglycine, Trimethylglycine Anhydre, Trimethylglycine Anhydrous.

What is Betaine Anhydrous?

Betaine anhydrous is a chemical that occurs naturally in the body, and can also be found in foods such as beets, spinach, cereals, seafood, and wine.

Betaine anhydrous is approved by the U.S. Food and Drug Administration (FDA) for treatment of high urine levels of a chemical called homocysteine (homocystinuria) in people with certain inherited disorders. High homocysteine levels are associated with heart disease, weak bones (osteoporosis), skeletal problems, and eye lens problems.

Betaine anhydrous is also used for treating high blood homocysteine levels, liver disease, depression, osteoarthritis, congestive heart failure (CHF), and obesity; for boosting the immune system; and for improving athletic performance. It is also used for preventing noncancerous tumors in the colon (colorectal adenomas).

Topically, betaine anhydrous is used as an ingredient in toothpastes to reduce the symptoms of dry mouth.

Effective for...

  • High homocysteine levels in the urine (homocystinuria). Taking betaine anyhydrous lowers homocysteine levels. Betaine anhydrous is FDA approved for treating this condition.

QUESTION

What causes tooth decay? See Answer

Possibly Effective for...

  • Dry mouth. Using betaine anhydrous in a toothpaste seems to reduce symptoms of dry mouth. Also, using a specific mouthwash (Xeros Dentaid) containing betaine anhydrous, xylitol, and sodium fluoride can improve dry mouth symptoms.
  • High homocysteine levels in the blood (hyperhomocysteinemia). Some research shows that supplementation with betaine anhydrous can decrease homocysteine levels in the blood of some but not all people. However, it is not clear if this also decreases heart disease risk. Taking betaine anhydrous might also lower homocysteine levels in the blood in people with kidney failure. However, betaine anhydrous does not seem to increase the homocysteine-lowering effects of folate in people with kidney failure.

Possibly Ineffective for...

  • Genetic disorder that causes intellectual disability (Angelman syndrome). Some research suggests that taking betaine anhydrous (Cystadane, Rare Disease Therapetics, Inc.) or betaine anhydrous together with folate, folic acid, creatine, and/or vitamin B12 does not prevent seizures or improve mental function in children with Angelman syndrome.

Insufficient Evidence to Rate Effectiveness for...

  • Noncancerous tumors in the colon and rectum (colorectal adenomas). Some research suggests that taking betaine anhydrous is not linked with a reduced risk of developing colorectal adenomas.
  • Exercise performance. Some research suggests that betaine might improve certain aspects of exercise performance, including body composition and strength, in experienced men who participate in strength training. However, betaine does not seem to improve strength in untrained men. Also, betaine does not appear to improve the ability to rehydrate after long distance running or sprinting.
  • Acid reflux. Early research suggests that taking a combination of betaine, melatonin, L-tryptophan, vitamin B6, folic acid, vitamin B12, and methionine daily can reduce symptoms of acid reflux.
  • Hepatitis C. Early research suggests that taking betaine anhydrous (Cystadane) and SAMe together with hepatitis C medications for 12 months can reduce the amount of active virus in people with hepatitis C who did not respond to treatment with hepatitis C medications alone.
  • Liver disease not due to alcohol use (nonalcoholic steatohepatitis, NASH). Developing research suggests that betaine anhydrous might improve liver disease in people with NASH.
  • Sunburn. Early research suggests that applying a specific betaine-containing cream (Physiogel Al) daily for one month before ultraviolet (UV) light exposure can reduce redness caused by UV rays. However, applying this cream only 20 minutes before exposure does not have any effect.
  • Nervous system disorder called Rett syndrome. Early research suggests that taking a combination of folate and betaine daily for 12 months does not improve growth, development, or function in girls with Rett syndrome.
  • Weight loss. In one small study, adding betaine anhydrous to a low-calorie diet did not produce extra weight loss in obese adults
  • Other conditions.
More evidence is needed to rate the effectiveness of betaine anhydrous for these uses.

How does Betaine Anhydrous work?

A form of betaine called betaine anhydrous helps in the metabolism of homocysteine, a chemical involved in the normal function of many different parts of the body, including blood, bones, eyes, heart, nerves, and the brain. Betaine anhydrous prevents the buildup of homocysteine seen in people who have problems with its metabolism from birth.

Are there safety concerns?

Betaine anhydrous is LIKELY SAFE for most children and adults when taken by mouth appropriately. It can cause some minor side effects. These include nausea, stomach upset, and diarrhea.

Betaine anhydrous is also available as a prescription drug in the U.S. Prescription betaine anhydrous is standardized, which means it contains a set dose of active chemicals.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking betaine anhydrous if you are pregnant or breast feeding. Stay on the safe side and avoid use.

High cholesterol: Betaine anhydrous can increase levels of total and low-density lipoprotein (LDL or “good”) cholesterol in healthy people, obese people, and people with kidney failure. Using betaine might make already high cholesterol levels even higher. People with high cholesterol should use betaine anhydrous cautiously.

Dosing considerations for Betaine Anhydrous.

The following doses have been studied in scientific research:

BY MOUTH:

  • For a condition called homocystinuria: A maintenance dose of 3 grams is usually taken twice daily in both adults and children. In children, the dose usually starts low and is gradually raised to this level. For children under three years old, the starting dose is 100 mg/kg per day; the next week the dose is raised to 200 mg/kg per day for the week; the following week, the dose is raised to 300 mg/kg per day for the week, and so on until the maintenance dose is reached. All patients can receive dose increases until the level of homocysteine in the blood is very low or too low to measure; sometimes doses up to 20 grams per day are needed to achieve this. Dissolve the powder in water immediately before taking.

CONTINUE SCROLLING FOR RELATED SLIDESHOW

SLIDESHOW

Top Problems in Your Mouth See Slideshow

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Health Solutions From Our Sponsors

Reviewed on 9/17/2019
References

Abdelmalek, M. F., Sanderson, S. O., Angulo, P., Soldevila-Pico, C., Liu, C., Peter, J., Keach, J., Cave, M., Chen, T., McClain, C. J., and Lindor, K. D. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009;50(6):1818-1826. View abstract.

Apicella, J. M., Lee, E. C., Bailey, B. L., Saenz, C., Anderson, J. M., Craig, S. A., Kraemer, W. J., Volek, J. S., and Maresh, C. M. Betaine supplementation enhances anabolic endocrine and Akt signaling in response to acute bouts of exercise. Eur J Appl.Physiol 2013;113(3):793-802. View abstract.

Armstrong, L. E., Casa, D. J., Roti, M. W., Lee, E. C., Craig, S. A., Sutherland, J. W., Fiala, K. A., and Maresh, C. M. Influence of betaine consumption on strenuous running and sprinting in a hot environment. J Strength.Cond.Res 2008;22(3):851-860. View abstract.

Atkinson, W., Elmslie, J., Lever, M., Chambers, S. T., and George, P. M. Dietary and supplementary betaine: acute effects on plasma betaine and homocysteine concentrations under standard and postmethionine load conditions in healthy male subjects. Am J Clin Nutr 2008;87(3):577-585. View abstract.

Atkinson, W., Slow, S., Elmslie, J., Lever, M., Chambers, S. T., and George, P. M. Dietary and supplementary betaine: effects on betaine and homocysteine concentrations in males. Nutr Metab Cardiovasc.Dis 2009;19(11):767-773. View abstract.

Bakker, C. V., Blomeke, B., Coenraads, P. J., and Schuttelaar, M. L. Ascaridole, a sensitizing component of tea tree oil, patch tested at 1% and 5% in two series of patients. Contact Dermatitis 2011;65(4):240-241. View abstract.

Balkan, J., Oztezcan, S., Kucuk, M., Cevikbas, U., Kocak-Toker, N., and Uysal, M. The effect of betaine treatment on triglyceride levels and oxidative stress in the liver of ethanol-treated guinea pigs. Exp Toxicol.Pathol. 2004;55(6):505-509. View abstract.

Barak, A. J., Beckenhauer, H. C., Badakhsh, S., and Tuma, D. J. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res 1997;21(6):1100-1102. View abstract.

Barak, AJ., Beckenhauer, HC., Mailliard, ME., Kharbanda, KK., and Tuma, DJ. Betaine lowers elevated s-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats. J Nutr. 2003;133(9):2845-2848.

Bidulescu, A., Chambless, L. E., Siega-Riz, A. M., Zeisel, S. H., and Heiss, G. Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. BMC.Cardiovasc.Disord. 2007;7:20. View abstract.

Bird, L. M., Tan, W. H., Bacino, C. A., Peters, S. U., Skinner, S. A., Anselm, I., Barbieri-Welge, R., Bauer-Carlin, A., Gentile, J. K., Glaze, D. G., Horowitz, L. T., Mohan, K. N., Nespeca, M. P., Sahoo, T., Sarco, D., Waisbren, S. E., and Beaudet, A. L. A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am J Med Genet.A 2011;155A(12):2956-2963. View abstract.

Bishop, L., Kanoff, R., Charnas, L., Krenzel, C., Berry, S. A., and Schimmenti, L. A. Severe methylenetetrahydrofolate reductase (MTHFR) deficiency: a case report of nonclassical homocystinuria. J Child Neurol. 2008;23(7):823-828. View abstract.

Bonig, H., Daublin, G., Schwahn, B., and Wendel, U. Psychotic symptoms in severe MTHFR deficiency and their successful treatment with betaine. Eur.J.Pediatr. 2003;162(3):200-201. View abstract.

Bostom, A. G., Shemin, D., Nadeau, M. R., Shih, V., Stabler, S. P., Allen, R. H., and Selhub, J. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 1995;113(1):129-132. View abstract.

Brattstrom, L., Wilcken, D. E., Ohrvik, J., and Brudin, L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 12-8-1998;98(23):2520-2526. View abstract.

Brouwer, I. A., Verhoef, P., and Urgert, R. Betaine supplementation and plasma homocysteine in healthy volunteers. Arch.Intern.Med. 9-11-2000;160(16):2546-2547. View abstract.

Burke, A. E., Barnhart, K., Jensen, J. T., Creinin, M. D., Walsh, T. L., Wan, L. S., Westhoff, C., Thomas, M., Archer, D., Wu, H., Liu, J., Schlaff, W., Carr, B. R., and Blithe, D. Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial. Obstet.Gynecol. 2010;116(6):1265-1273. View abstract.

Calow, T., Oberle, K., Bruckner-Tuderman, L., Jakob, T., and Schumann, H. Contact dermatitis due to use of Octenisept in wound care. J Dtsch.Dermatol Ges. 2009;7(9):759-765. View abstract.

Cave, M., Deaciuc, I., Mendez, C., Song, Z., Joshi-Barve, S., Barve, S., and McClain, C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007;18(3):184-195. View abstract.

Chaabene-Masmoudi, A., Mesrati, F., Zittoun, J., and Landrieu, P. Insidious peripheral neuropathy occurring under treatment in infantile MTHFR deficiency. J Inherit.Metab Dis 2009;32 Suppl 1:S303-S306. View abstract.

Cheng, K. H., Hung, M. C., Chen, S. J., Kao, C. H., and Niu, D. M. Lenticular subluxation in a patient with homocystinuria undetected by neonatal screening. J Chin Med Assoc. 2007;70(12):562-564. View abstract.

Cholewa, J. M., Wyszczelska-Rokiel, M., Glowacki, R., Jakubowski, H., Matthews, T., Wood, R., Craig, S. A., and Paolone, V. Effects of betaine on body composition, performance, and homocysteine thiolactone. J Int Soc.Sports Nutr 2013;10(1):39. View abstract.

Cressey, B. D. and Scheinman, P. L. Systemic allergic dermatitis of the lips resulting from allergy to an antimicrobial agent in a contact lens disinfecting solution. Contact Dermatitis 2012;67(4):239-240. View abstract.

Davies, S. E., Chalmers, R. A., Randall, E. W., and Iles, R. A. Betaine metabolism in human neonates and developing rats. Clin.Chim.Acta 12-30-1988;178(3):241-249. View abstract.

del Favero, S., Roschel, H., Artioli, G., Ugrinowitsch, C., Tricoli, V., Costa, A., Barroso, R., Negrelli, A. L., Otaduy, M. C., da Costa, Leite C., Lancha-Junior, A. H., and Gualano, B. Creatine but not betaine supplementation increases muscle phosphorylcreatine content and strength performance. Amino Acids 2012;42(6):2299-2305. View abstract.

Fernandez-Figares, I., Wray-Cahen, D., Steele, N. C., Campbell, R. G., Hall, D. D., Virtanen, E., and Caperna, T. J. Effect of dietary betaine on nutrient utilization and partitioning in the young growing feed-restricted pig. J Anim Sci 2002;80(2):421-428. View abstract.

Forges, T., Chery, C., Audonnet, S., Feillet, F., and Gueant, J. L. Life-threatening methylenetetrahydrofolate reductase (MTHFR) deficiency with extremely early onset: characterization of two novel mutations in compound heterozygous patients. Mol.Genet.Metab 2010;100(2):143-148. View abstract.

Garcia-Jimenez, M. C., Baldellou, A., Garcia-Silva, M. T., Dalmau-Serra, J., Garcia-Cazorla, A., Gomez-Lopez, L., Giner, C. P., Luengo, O. A., Pena, Quintana L., Couce, M. L., Martinez-Pardo, M., and Lambruschini, N. [Epidemiological study of the metabolic diseases with homocystinuria in Spain]. An Pediatr.(Barc.) 2012;76(3):133-139. View abstract.

Glaze, D. G., Percy, A. K., Motil, K. J., Lane, J. B., Isaacs, J. S., Schultz, R. J., Barrish, J. O., Neul, J. L., O'Brien, W. E., and Smith, E. O. A study of the treatment of Rett syndrome with folate and betaine. J Child Neurol. 2009;24(5):551-556. View abstract.

Hoffman, J. R., Ratamess, N. A., Kang, J., Gonzalez, A. M., Beller, N. A., and Craig, S. A. Effect of 15 days of betaine ingestion on concentric and eccentric force outputs during isokinetic exercise. J Strength.Cond.Res 2011;25(8):2235-2241. View abstract.

Horrocks, A. Prontosan wound irrigation and gel: management of chronic wounds. Br J Nurs. 12-14-2006;15(22):1222, 1224-1222, 1228. View abstract.

Kelly, T. L., Neaga, O. R., Schwahn, B. C., Rozen, R., and Trasler, J. M. Infertility in 5,10-methylenetetrahydrofolate reductase (MTHFR)-deficient male mice is partially alleviated by lifetime dietary betaine supplementation. Biol Reprod 2005;72(3):667-677. View abstract.

Kemeny, L., Koreck, A., Kis, K., Kenderessy-Szabo, A., Bodai, L., Cimpean, A., Paunescu, V., Raica, M., and Ghyczy, M. Endogenous phospholipid metabolite containing topical product inhibits ultraviolet light-induced inflammation and DNA damage in human skin. Skin Pharmacol Physiol 2007;20(3):155-161. View abstract.

Kharbanda, K. K., Rogers, D. D., Mailliard, M. E., Siford, G. L., Barak, A. J., Beckenhauer, H. C., Sorrell, M. F., and Tuma, D. J. A comparison of the effects of betaine and S-adenosylmethionine on ethanol-induced changes in methionine metabolism and steatosis in rat hepatocytes. J Nutr 2005;135(3):519-524. View abstract.

Knopman, D. and Patterson, M. An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. Alzheimer Dis.Assoc.Disord. 2001;15(3):162-165. View abstract.

Knopp, E. and Watsky, K. Eyelid dermatitis: contact allergy to 3-(dimethylamino)propylamine. Dermatitis 2008;19(6):328-333. View abstract.

Lever, M., Atkinson, W., Slow, S., Chambers, S. T., and George, P. M. Plasma and urine betaine and dimethylglycine variation in healthy young male subjects. Clin Biochem. 2009;42(7-8):706-712. View abstract.

Lever, M., Sizeland, P. C., Bason, L. M., Hayman, C. M., Robson, R. A., and Chambers, S. T. Abnormal glycine betaine content of the blood and urine of diabetic and renal patients. Clin.Chim.Acta 10-14-1994;230(1):69-79. View abstract.

Lin, N. C., Niu, D. M., Loong, C. C., Hsia, C. Y., Tsai, H. L., Yeh, Y. C., Tsou, M. Y., and Liu, C. S. Liver transplantation for a patient with homocystinuria. Pediatr.Transplant. 2012;16(7):E311-E314. View abstract.

Liu, L. L., Hou, X. L., Zhou, C. L., and Yang, Y. L. [Combined methylmalonic aciduria and homocysteinemia with hydrocephalus as an early presentation: a case report]. Zhongguo Dang.Dai Er.Ke.Za Zhi. 2013;15(4):313-315. View abstract.

Lopez-Jornet, P., Camacho-Alonso, F., and Rodriguez-Aguado, C. Evaluation of the clinical efficacy of a betaine-containing mouthwash and an intraoral device for the treatment of dry mouth. J Oral Pathol.Med 2012;41(3):201-206. View abstract.

Menni, F., Testa, S., Guez, S., Chiarelli, G., Alberti, L., and Esposito, S. Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Pediatr.Nephrol. 2012;27(8):1401-1405. View abstract.

Miglio, F., Rovati, L. C., Santoro, A., and Setnikar, I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung. 2000;50(8):722-727. View abstract.

Moat, S. J., Madhavan, A., Taylor, S. Y., Payne, N., Allen, R. H., Stabler, S. P., Goodfellow, J., McDowell, I. F., Lewis, M. J., and Lang, D. High- but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 2006;36(12):850-859. View abstract.

Moore, C., Addy, M., and Moran, J. Toothpaste detergents: a potential source of oral soft tissue damage? Int J Dent.Hyg. 2008;6(3):193-198. View abstract.

Muller, P., Horneff, G., and Hennermann, J. B. [A rare inborn error of intracellular processing of cobalamine presenting with microcephalus and megaloblastic anemia: a report of 3 children]. Klin.Padiatr. 2007;219(6):361-367. View abstract.

Navratil, T., Petr, M., Senholdova, Z., Pristoupilova, K., Pristoupil, T. I., Heyrovsky, M., Pelclova, D., and Kohlikova, E. Diagnostic significance of urinary thiodiglycolic acid as a possible tool for studying the role of vitamins B12 and folates in the metabolism of thiolic substances. Physiol Res 2007;56(1):113-122. View abstract.

Olthof, M. R., van Vliet, T., Boelsma, E., and Verhoef, P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J.Nutr. 2003;133(12):4135-4138. View abstract.

Peters, S. U., Bird, L. M., Kimonis, V., Glaze, D. G., Shinawi, L. M., Bichell, T. J., Barbieri-Welge, R., Nespeca, M., Anselm, I., Waisbren, S., Sanborn, E., Sun, Q., O'Brien, W. E., Beaudet, A. L., and Bacino, C. A. Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid. Am J Med Genet.A 2010;152A(8):1994-2001. View abstract.

Prasad, A. N., Rupar, C. A., and Prasad, C. Methylenetetrahydrofolate reductase (MTHFR) deficiency and infantile epilepsy. Brain Dev. 2011;33(9):758-769. View abstract.

Roblin, X., Pofelski, J., and Zarski, J. P. [Steatosis, chronic hepatitis virus C infection and homocysteine]. Gastroenterol.Clin Biol 2007;31(4):415-420. View abstract.

Rojas-Cano, M. L., Lara, L., Lachica, M., Aguilera, J. F., and Fernandez-Figares, I. Influence of betaine and conjugated linoleic acid on development of carcass cuts of Iberian pigs growing from 20 to 50 kg body weight. Meat.Sci 2011;88(3):525-530. View abstract.

Romanelli, M., Dini, V., Barbanera, S., and Bertone, M. S. Evaluation of the efficacy and tolerability of a solution containing propyl betaine and polihexanide for wound irrigation. Skin Pharmacol Physiol 2010;23 Suppl:41-44. View abstract.

Saad, S., Greenman, J., and Shaw, H. Comparative effects of various commercially available mouthrinse formulations on oral malodor. Oral Dis 2011;17(2):180-186. View abstract.

Sakura, N., Ono, H., Nomura, S., Ueda, H., and Fujita, N. Betaine dose and treatment intervals in therapy for homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. J.Inherit.Metab Dis. 1998;21(1):84-85. View abstract.

Schiff, M., Benoist, J. F., Tilea, B., Royer, N., Giraudier, S., and Ogier de, Baulny H. Isolated remethylation disorders: do our treatments benefit patients? J Inherit.Metab Dis 2011;34(1):137-145. View abstract.

Schwab, U., Alfthan, G., Aro, A., and Uusitupa, M. Long-term effect of betaine on risk factors associated with the metabolic syndrome in healthy subjects. Eur J Clin Nutr 2011;65(1):70-76. View abstract.

Schwab, U., Torronen, A., Meririnne, E., Saarinen, M., Alfthan, G., Aro, A., and Uusitupa, M. Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. J Nutr 2006;136(1):34-38. View abstract.

Schwahn, B. C., Chen, Z., Laryea, M. D., Wendel, U., Lussier-Cacan, S., Genest, J., Jr., Mar, M. H., Zeisel, S. H., Castro, C., Garrow, T., and Rozen, R. Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J. 2003;17(3):512-514. View abstract.

Schwahn, B. C., Laryea, M. D., Chen, Z., Melnyk, S., Pogribny, I., Garrow, T., James, S. J., and Rozen, R. Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. Biochem J 9-15-2004;382(Pt 3):831-840. View abstract.

Schwahn, B. C., Wendel, U., Lussier-Cacan, S., Mar, M. H., Zeisel, S. H., Leclerc, D., Castro, C., Garrow, T. A., and Rozen, R. Effects of betaine in a murine model of mild cystathionine-beta-synthase deficiency. Metabolism 2004;53(5):594-599. View abstract.

Selicharova, I., Korinek, M., Demianova, Z., Chrudinova, M., Mladkova, J., and Jiracek, J. Effects of hyperhomocysteinemia and betaine-homocysteine S-methyltransferase inhibition on hepatocyte metabolites and the proteome. Biochim.Biophys.Acta 2013;1834(8):1596-1606. View abstract.

Sharma, A. P., Greenberg, C. R., Prasad, A. N., and Prasad, C. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr.Nephrol. 2007;22(12):2097-2103. View abstract.

Ship, J. A., McCutcheon, J. A., Spivakovsky, S., and Kerr, A. R. Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth. J Oral Rehabil. 2007;34(10):724-732. View abstract.

Steenge, G. R., Verhoef, P., and Katan, M. B. Betaine supplementation lowers plasma homocysteine in healthy men and women. J.Nutr. 2003;133(5):1291-1295. View abstract.

Surtees, R., Bowron, A., and Leonard, J. Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine beta-synthase deficiency: the effect of treatment. Pediatr Res 1997;42(5):577-582. View abstract.

Trepanowski, J. F., Farney, T. M., McCarthy, C. G., Schilling, B. K., Craig, S. A., and Bloomer, R. J. The effects of chronic betaine supplementation on exercise performance, skeletal muscle oxygen saturation and associated biochemical parameters in resistance trained men. J Strength.Cond.Res 2011;25(12):3461-3471. View abstract.

Tsuji, M., Takagi, A., Sameshima, K., Iai, M., Yamashita, S., Shinbo, H., Furuya, N., Kurosawa, K., and Osaka, H. 5,10-Methylenetetrahydrofolate reductase deficiency with progressive polyneuropathy in an infant. Brain Dev. 2011;33(6):521-524. View abstract.

Ucar, S. K., Koroglu, O. A., Berk, O., Yalaz, M., Kultursay, N., Blom, H. J., and Coker, M. Titration of betaine therapy to optimize therapy in an infant with 5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 2010;169(2):241-243. View abstract.

Urreizti, R., Moya-Garcia, A. A., Pino-Angeles, A., Cozar, M., Langkilde, A., Fanhoe, U., Esteves, C., Arribas, J., Vilaseca, M. A., Perez-Duenas, B., Pineda, M., Gonzalez, V., Artuch, R., Baldellou, A., Vilarinho, L., Fowler, B., Ribes, A., Sanchez-Jimenez, F., Grinberg, D., and Balcells, S. Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency. Clin Genet. 2010;78(5):441-448. View abstract.

van Guldener, C., Janssen, M. J., de Meer, K., Donker, A. J., and Stehouwer, C. D. Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients. J.Intern.Med. 1999;245(2):175-183. View abstract.

van Guldener, C., Janssen, M. J., Lambert, J., ter Wee, P. M., Donker, A. J., and Stehouwer, C. D. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit.Dial.Int 1998;18(3):282-289. View abstract.

Werbach, M. R. Melatonin for the treatment of gastroesophageal reflux disease. Altern.Ther Health Med 2008;14(4):54-58. View abstract.

Wilcken, D. E., Dudman, N. P., and Tyrrell, P. A. Homocystinuria due to cystathionine beta-synthase deficiency--the effects of betaine treatment in pyridoxine-responsive patients. Metabolism 1985;34(12):1115-1121. View abstract.

Yap, S., Boers, G. H., Wilcken, B., Wilcken, D. E., Brenton, D. P., Lee, P. J., Walter, J. H., Howard, P. M., and Naughten, E. R. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler.Thromb.Vasc.Biol 2001;21(12):2080-2085. View abstract.

Yepes-Nunez, J. J., Gomez Rendon, F. E., and Nunez-Rinta, R. Allergic contact dermatitis to cocamidopropyl betaine in Colombia. Allergol.Immunopathol.(Madr.) 2012;40(2):126-128. View abstract.

Yokoi, K., Ito, T., Ohkubo, Y., Sumi, S., Ueta, A., Sugiyama, N., and Togari, H. Long follow up of betaine therapy in two Japanese siblings with cystathionine beta-synthase deficiency. Pediatr.Int 2008;50(5):694-695. View abstract.

Zeisel, S. H., Mar, M. H., Howe, J. C., and Holden, J. M. Concentrations of choline-containing compounds and betaine in common foods. J.Nutr. 2003;133(5):1302-1307. View abstract.

Zhang, Y., Song, J. Q., Liu, P., Yan, R., Dong, J. H., Yang, Y. L., Wang, L. F., Jiang, Y. W., Zhang, Y. H., Qin, J., and Wu, X. R. [Clinical studies on fifty-seven Chinese patients with combined methylmalonic aciduria and homocysteinemia]. Zhonghua Er.Ke.Za Zhi. 2007;45(7):513-517. View abstract.

Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-7.. View abstract.

Alfthan G, Tapani K, Nissinen K, et al. The effect of low doses of betaine on plasma homocysteine in healthy volunteers. Br J Nutr 2004;92:665-9. View abstract.

Anon. Betaine. Monograph. Altern Med Rev 2003;8:193-6. View abstract.

Barak AJ, Beckenhauer HC, Tuma DJ. Betaine, ethanol, and the liver: a review. Alcohol 1996;13:395-8. View abstract.

Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57. View abstract.

Brouwer IA, Verhoef P, Urgert R. Betaine supplementation and plasma homocysteine in healthy volunteers (letter). Arch Intern Med 2000;160:2546-7.

Cho E, Willett WC, Colditz GA, et al. Dietary choline and betaine and the risk of distal colorectal adenoma in women. J Natl Cancer Inst 2007;99:1224-31. View abstract.

Craig SA. Betaine in human nutrition. Am J Clin Nutr 2004;80:539-49. View abstract.

Cystadane (betaine anhydrous for oral solution) Package insert. Orphan Medical, Inc. Minnetonka, MN. November 2005.

Filipowicz M., Bernsmeier C., Terracciano L., Duong F. H., Heim M. H. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One 2010;5(11):e15492. View abstract.

Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.. View abstract.

Mar MH, Zeisel SH. Betaine in wine: answer to the French paradox? Med Hypotheses 1999;53:383-5. View abstract.

Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27. View abstract.

McCarty MF. Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy. Med Hypotheses 2000;55:189-94. View abstract.

McGregor DO, Dellow WJ, Robson RA, et al. Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. Kidney Int 2002;61:1040-6. View abstract.

Olthof MR, van Vliet T, Verhoef P, et al. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans. PloS Med 2005;2:e135. View abstract.

Periera Rde S. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res 2006;41:195-200. View abstract.

Schwab U, Torronen A, Toppinen L, et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002;76:961-7. View abstract.

Schwahn BC, Hafner D, Hohlfeld T, et al. Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br J Clin Pharmacol 2003;55:6-13. View abstract.

Soderling E, Le Bell A, Kirstila V, Tenovuo J. Betaine-containing toothpaste relieves subjective symptoms of dry mouth. Acta Odontol Scand 1998;56:65-9. View abstract.

Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 1983;309:448-53. View abstract.